News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.



Ethereum Sees 2-Year Peak in Network Activity Despite $ETH Price Downturn
BlockchainReporter·2025/12/31 12:12
Standard Chartered Reveals Incredible Ripple (XRP) Prediction for 2026!
BitcoinSistemi·2025/12/31 12:09
EUR/JPY edges higher, approaching 184.00 as Yen broadly softens
101 finance·2025/12/31 12:06

Ethereum price bulls eye breakout as descending resistance squeezes price, where will it go?
Crypto.News·2025/12/31 12:00
Ethereum Network Activity Surges Unusually – What Does it Mean For ETH Price?
BeInCrypto·2025/12/31 11:54
Lighter Valuation Surpasses Pump.fun and Jupiter: Can LIT Overtake Hyperliquid?
BeInCrypto·2025/12/31 11:54

Pump.fun (PUMP) To Climb Higher? This Emerging Bullish Pattern Formation Suggests So!
Coinsprobe·2025/12/31 11:48
Grayscale Files to Convert Bittensor Trust into First U.S. Spot ETF for TAO Tokens
Cryptonewsland·2025/12/31 11:42
Flash
21:26
JPMorgan executive: Yield-bearing stablecoins can easily evolve into "shadow banks"Jinse Finance reported that on June 30, two senior executives from JPMorgan stated that if stablecoin innovation allows for interest generation and yields, it could easily evolve into “shadow banking”. Umar Farooq, Global Co-Head of Payments, and Peter Muriungi, CEO of Digital Assets and Blockchain Solutions at the company, issued a statement calling for the United States to establish a comprehensive digital asset framework, though without directly referencing the “Clarity Act”. The statement noted that “tokenization and programmable money” offer key innovations for global payments and 24/7 real-time settlement. However, yield-bearing stablecoins could veer into “shadow banking”, so stablecoins should be subject to “the same regulatory standards as traditional deposit products”.
21:22
Praxis Precision Medicines shares fall after hours as the US FDA extends the review period for its epilepsy drug by 3 monthsAffected by this news, the company's stock price fell 5.9% after hours. The FDA has set a revised PDUFA (Prescription Drug User Fee Act) target action date for December 27, 2026, instead of the previous PDUFA date of September 27. This postponement occurred after Praxis submitted an additional sensitivity analysis regarding existing clinical data. The FDA has classified this submission as a major amendment, thereby allowing additional review time. The FDA has not requested any new clinical studies nor raised any concerns related to safety or manufacturing.
21:15
Aeon Acquisition I Corp. has announced through a filing with the U.S. Securities and Exchange Commission that its Class A common stock, warrants, and rights will begin separate trading on July 1, 2026.This move means that these securities components, which were previously issued as unit combinations, will now be able to be bought and sold separately. Investors will have greater flexibility in configuring their portfolios and can adopt independent trading strategies for different securities components. This change is expected to provide higher liquidity to the market and may impact the valuation and trading dynamics of related securities.